PR Newswire BiotechOriginal article
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
Trial StartChoICE StudyPositive
AI Analysis
Summary
IceCure Medical announced that Adventist Health Glendale has become the first clinical site to enroll patients in the post-marketing ChoICE Study for low-risk breast cancer cryoablation treatment, with the site led by breast surgeon Dr. Dennis Holmes.
Clinical Trial Data
Phase
Post-marketing
Outcome Details
First clinical site enrolled in post-marketing ChoICE Study
Importance:4/10
Sentiment:
0.50
clinical trialbreast cancercryoablationpost-marketing studyIRB approval
Related Companies
Read the original article
Published by PR Newswire Biotech on August 6, 2026 12:05 PM